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Available online 22 February 2012Abstract Suspension bioreactors are an attractive alternative to static culture of human embryonic stem cells (hESCs) for the
generation of clinically relevant cell numbers in a controlled system. In this study, we have developed a scalable suspension culture
system using serum-free defined media with spinner flasks for hESC expansion as cell aggregates. With optimized cell seeding den-
sity and splitting interval, we demonstrate prolonged passaging and expansion of several hESC lines with overall expansion, yield,
viability andmaintenance of pluripotency equivalent to adherent culture. Human ESCsmaintained in suspension as aggregates can
be passaged at least 20 times to achieve over 1×1013 fold calculated expansion with high undifferentiation rate and normal
karyotype. Furthermore, the aggregates are able to differentiate to cardiomyocytes in a directed fashion. Finally, we show that
the cells can be cryopreserved in serum-free medium and thawed into adherent or suspension cultures to continue passaging
and expansion. We have successfully used this method under cGMP or cGMP-equivalent conditions to generate cell banks of several
hESC lines. Taken together, our suspension culture system provides a powerful approach for scale-up expansion of hESCs under
defined and serum-free conditions for clinical and research applications.
© 2012 Elsevier B.V. All rights reserved.Introduction
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doi:10.1016/j.scr.2012.02.001self-renewal capacity and the ability to differentiate to
cell types representing the three germ layers. They repre-
sent an important source for cell therapies in regenerative
medicine and the study of early human development. It is
important to develop reproducible and scalable cell culture
systems to support cell banking and to seed clinical scale
hESC differentiation production processes.
Conventionally, hESCs are propagated and banked using
adherent cell culture systems, which involve the use of feeder
cells or matrices. To achieve the production of clinical-grade
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culture systems with feeder-free, serum-free and defined
media and depend upon the use of defined or tumor derived
cell substrates in order to maintain hESCs in an undifferen-
tiated and diploid state (Li et al., 2005; Ludwig et al., 2006;
Melkoumian et al., 2010; Rodin et al., 2010; Villa-Diaz et al.,
2010; Wang et al., 2007; Xu et al., 2001). Despite improve-
ment in the reagents available for these culture systems, the
scaling up of adherent cell culture systems continues to re-
quire the use of an artificial substrate, the handling large num-
bers of culture vessels and detachment of cells from solid
phase during cell passaging and harvesting, making the pro-
cess of scaling up labor-intensive and time-consuming, poten-
tially affecting the reproducibility and quality of these cell
cultures. An advantage of adapting hESCs to suspension cul-
ture is the elimination of feeder layers and tumor derived or
synthetic matrices. Therefore, the development of robust sus-
pension culture scale-up technologies will accelerate the
entry of hESC therapeutics to clinical studies. While we and
others have produced hESC banks under cGLP and cGMP condi-
tions using adherent cell culture techniques (Crook et al.,
2007), the development of reproducible, scalable, serum-
free, and matrix-free suspension culture systems represents
significant progress towards controllable automation systems
for industrial manufacturing of clinical-grade hESC-based
therapeutics.
It has been previously demonstrated that hESCs are ex-
tremely vulnerable to apoptosis after single cell dissociation
(Amit et al., 2000; Reubinoff et al., 2000; Thomson et al.,
1998) and are therefore often manually passaged as mechan-
ically fragmented colonies or as small cell clumps to increase
cell survival rate and plating efficiency. Recently it was
demonstrated that ROCK inhibitors significantly increase
the survival of hESCs upon single cell dissociation (Harb et
al., 2008; Watanabe et al., 2007), allowing the use of enzy-
matic passaging methods. Furthermore, in the presence of a
ROCK inhibitor, Y-27632, single cell-dissociated hESCs can
efficiently form cell aggregates and grow in suspension
(Watanabe et al., 2007). Utilizing ROCK inhibitors, several
recent studies showed that hESCs can be maintained, serial
passaged, and expanded in an undifferentiated state in sus-
pension culture (Amit et al., 2010; Amit et al., 2011;
Krawetz et al., 2010; Olmer et al., 2010; Singh et al.,
2010; Steiner et al., 2010; Zweigerdt et al., 2011). These
studies described various types of suspension systems, in-
cluding low-attachment static plates, rotated dishes or Er-
lenmeyer flasks, and spinner flasks. Although the studies
using plate, Petri dish, or Erlenmeyer flask systems appeared
promising systems, the scalability was limited. Those utiliz-
ing spinner flasks are preferred for their potential scalability
as closed bioreactor systems. However, the long-term scal-
able expansion of hESC lines using spinner flasks has not
been demonstrated.
Despite the success of hESC suspension culture with spin-
ner flasks from previous studies, the cultures were reported
to yield either low expansion rates or low overall cell yield
(Krawetz et al., 2010; Singh et al., 2010). Using a spinner
flask for hESC suspension culture, Singh et al. showed a
2-fold expansion over 7 days when cells were seeded at
1×106cells/ml. In contrast, with a much lower cell seeding
density, 1.8×104cells/ml, Krawetz et al. reported a signifi-
cant expansion rate but a low cell yield, approximately5×105cells/ml over 6 days. To establish a scalable and effi-
cient suspension culture system for large-scale hESC produc-
tion, it will be necessary to further optimize culture
conditions to achieve a high expansion rate with a high
yield of hESCs.
The objective of this study was to develop a scalable hESC
suspension culture system that can be applied to GMP pro-
duction of hESCs. We showed that undifferentiated hESCs
can propagate in aggregate form in suspension culture with
addition of a ROCK inhibitor and retain characteristics of
undifferentiated hESCs. We then compared different de-
fined serum-free media conditions and determined seeding
density and cell splitting interval for the suspension culture
to optimize cell expansion rate, undifferentiation rate, and
cell yields. With the optimized culture conditions, we dem-
onstrated that the hESC suspension cultures can be main-
tained over extended culture times (up to 21 passages) in
spinner flasks and provide cell expansion rates and yields
comparable to that seen in adherent cell cultures. Cells har-
vested from this suspension system can be cryopreserved as
single cell suspensions using defined serum-free freezing
medium. Cryopreserved cells retained high viability after
thaw and could be plated, passaged, and expanded in adher-
ent or suspension cultures. Using this system we practically
generated 3 master cell banks under GLP and GMP condi-
tions, demonstrating the feasibility of our suspension culture
system for mass hESC production.Results
Adaptation of hESCs to suspension culture
In order to reduce the potential for MEF contamination of
hESC suspension culture and to achieve fully defined cell cul-
ture conditions, we adapted all hESC lines to MEF-free and
serum-free hESC adherent culture prior to adaptation to sus-
pension culture. Before initiation of suspension cultures,
hESCs maintained on MEF were adapted to culture conditions
using a well-defined matrix, CELLstart, with a serum-free and
defined medium, StemPro hESC SFM. Three cell lines, HES-2,
H1, and H9, were adapted to these culture conditions and
appeared to grow as a monolayer (Supplementary Figure 1A).
Cells cultured under these conditions expressed pluripotency
markers, Tra-1-60, Tra-1-81, SSEA-4, and Oct-4 (Supplementa-
ry Figure 1B). Human ES cells grown in this defined culture sys-
tem were able to form teratomas containing 3 germ layers of
various cell lineages after injection into immunocompromised
mice (data not shown). Cells were maintained on CELLstart
cultures with StemPro hESC SFM for over 3 passages before
final adaptation to suspension conditions.
Initial experiments to adapt adherent hESCs to suspension
culture focused on determining whether undifferentiated
hESCs could survive as aggregates in suspension culture.
Previous studies have shown that ROCK inhibitor increases
hESC survival after dissociation to single cells and allows single
hESCs to survive in suspension in the form of aggregates
(Watanabe et al., 2007). Therefore, cells were pretreated
with a ROCK inhibitor, Y-27632, for 1 h before single cell disso-
ciation. To achieve a better adaptation in suspension, StemPro
hESC SFM used for adherent culture of parent hESCs was used
as a base medium for suspension culture. In this experiment,
390 V.C. Chen et al.dissociated single cells were seeded into this medium contain-
ing Y-27632 in 6-well plates with 70 rpm of orbital shaking to
prevent cell attachment. Consistent with reports from other
groups, we found that hESCs were able to form cell aggregates
and continued to grow in size in the presence of Y-27632
(Figure 1A), while cultures without Y-27632 remained as single
cells and failed to expand (Figure 1B). This result indicates
that hESCs from adherent cultures maintained on CELLstart
can survive and proliferate as cell aggregates in suspension
with addition of Y-27632.Characterization of hESC aggregates maintained in
suspension culture
We next examined whether hESCs in these cell aggregates
retain characteristics of undifferentiated hESCs. The sizeFigure 1 Growth of hESCs in suspension. (A) H9 hESCs grown on CE
low-attachment plates containing StemPro hESC SFM. In the presence
in single cells in the absence of Y-27632 after 3 days of culture. (C
E-cadherin, Tra-1-60, and Nanog and were imaged by confocal
well-defined edges as cultured back on MEF. (E) The colonies weredistributions of H9 cell aggregates at days 2 and 3 were ap-
proximately 100–120 and 150–200 μm, respectively. Cell ag-
gregates harvested from day 2 or 3 suspension culture were
assessed for expression of the pluripotency markers Nanog,
Oct-4, E-cadherin, and Tra-1-60 and analyzed by confocal
fluorescent imaging (Figure 1C). The results of z-stack scan-
ning showed that cells inside aggregates showed nuclear stain-
ing for Oct-4 and Nanog and surface staining for E-cadherin
and Tra-1-60, indicating hESCs in aggregates remained undif-
ferentiated. Cell aggregates harvested from day 4 suspension
culture were re-plated onto MEF to examine if they retained
growth characteristics of hESCs in adherent culture. Our re-
sults showed that these cell aggregates could be successfully
seeded onto MEF and formed typical compact hESC colonies
with well-defined edges (Figure 1D). The colonies grown on
MEF also displayed strong staining of alkaline phosphatase
(Figure 1E), indicative of undifferentiated hESCs. TakenLLstart were single cell-dissociated and cultured in suspension in
of Y-27632, hESCs formed cell aggregates, (B) while cells stayed
) Day 2 cell aggregates were whole-mount stained with Oct-4,
microscopy. (D) The cell aggregates formed colonies with
shown positive for alkaline phosphatase staining.
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retain the characteristics of undifferentiated hESCs.
Selection of media for suspension culture
After determining that hESCs survive as aggregates in the
presence of ROCK inhibitor, we assessed different media for-
mulations suitable for clinical applications, including mTeSR
complete medium and StemPro hESC SFM supplemented
with 8 or 40 ng/ml bFGF. We assessed 2 different hESC
lines, HES-2 and H9, in these media conditions for cell viabil-
ity, aggregate size and homogeneity of aggregates. Our goal
was to identify a media formulation that can support cell
growth in small and homogeneous aggregates with high
viability and undifferentiated rate.
Prior tomoving to spinner flasks for large-scale expansion,
we tested these 3 conditions, mTeSR, and StemPro hESC SFM
with 8, or 40 ng/ml bFGF, for growing hESCs in suspension in
small scale of culture vessels. Single cell-dissociated HES-2
and H9 cells were seeded in suspension at 2×105cells/ml
into these 3 conditions containing Y-27632 in 6-well plates
with orbital shaking. At day 1, cell aggregates were observed
in all media conditions (Figure 2A and Supplementary
Figure 2A). In general, cell aggregates generated in StemPro
appeared more homogeneous, while cell aggregates generat-
ed in mTeSR were larger and heterogeneous in size. We also
found that cells appeared to form more cell aggregates in
StemPro media. At day 3, cell aggregates appeared more
compact in all 3 media conditions. Cell aggregates formed
in StemPro media were more uniform, and usually less than
200 μm in diameter, while many of cell aggregates formed
in the mTeSR medium exceeded 200 μm (Figure 2A and Sup-
plementary Figure 2A). Over time in culture, cell aggregates
continued to gain in size. By day 6, HES-2 cell aggregates cul-
tured in StemPro media started to show vacuolization, a
sign of differentiation, but vacuolization was not observed
in H9 cell aggregates in all media conditions (Supplementary
Figure 2A). Flow cytometry analysis revealed that over 90% of
the HES-2 cell population expressed pluripotency markers at
day 3 but the positive population in all media conditions de-
clined at day 6 (Supplementary Figure 2B), suggesting differ-
entiation begins to occur between days 3 and 6. In contrast,
in the H9 line, over 90% of the cell population retained ex-
pression of pluripotency markers in all media conditions
at days 3 and 6 (Figure 2B). Viability of both hESC lines in
these media conditions was found to be comparable
(Figure 2C and Supplementary Figure 2C). At day 3, viability
ranged from 90 to 98% which slightly decreased to 83–93%
by day 6. For cell yields, HES-2 and H9 cultured with StemPro
showed higher cell numbers at days 3 and 6, particularly with
40 ng/ml bFGF (Figure 2D and Supplementary Figure 2D).
Taken together, these data suggest that StemPro hESC SFM
with 40 ng/ml bFGF is superior in supporting both HES-2 and
H9 hESCs to form small and homogeneous cell aggregates
and to produce higher cell yields in suspension culture.
Determination of seeding density and cell split
interval for suspension culture
As cell aggregates gain in size, it is more difficult for cy-
tokines and nutrients to penetrate the aggregates whichcould result in increased differentiation and decreased pro-
liferation. Consistent with this, our previous results have
shown that expression of pluripotency markers of HES-2
cells decreased as the aggregates increased in size between
days 3 and 6. Therefore we assessed passaging HES-2 and H9
cultures during this time period. Dissociated single cells
were seeded in spinner flasks containing StemPro hESC SFM
with 40 ng/ml bFGF and Y-27632 at 1.5 and 2.5×105cells/ml.
In spinner flasks (70 rpm), hESCs formed homogeneous cell
aggregates. Cells were harvested from days 1 to 6 for analysis.
At day 1, cell aggregates from low seeding density appeared
slightly smaller and the number of aggregates also appeared
lower. However, cell aggregates fromdays 1 to 4 did show com-
pact sphere morphology (Figure 3A and Supplementary Figure
3A). At day 5, HES-2 cell aggregates fromboth seeding densities
started to show evidence of vacuolization (Supplementary Fig-
ure 3A). A minor vacuolization was also noticed at the surface
of some H9 cell aggregates (Figure 3A). Flow cytometric analy-
sis of pluripotency markers revealed that positive populations
for Tra-1-60, Tra-1-81, and OCT-4 significantly declined after
day 4 in both HES-2 and H9 cells seeded at either cell density
(Figure 3B and Supplementary Figure 3B). Despite the decline
of the undifferentiated population after day 4, suspension cul-
tures retained high viability, approximately 90% for 6 days
(Figure 3C and Supplementary Figure 3C). However, cell
growth rates started to decrease after day 4 (Figure 3D and
Supplementary Figure 3D). At high cell seeding density,
2.5×105cells/ml, the suspension cultures generated higher
cell yields, approximately 1×106cells/ml after 3 days in cul-
ture. Taken together, these results indicate that cells in sus-
pension culture using spinner flasks begin differentiating and
decreasing in expansion rate after day 4, and thus we deter-
mined that the optimal splitting interval is at day 3 or 4.Serial passaging and expansion of suspension culture
In order to scale-up hESCs for large-scale banking, we
assessed whether the suspension culture conditions de-
scribed in previous sections were able to consistently main-
tain cell viability and expansion rate in spinner flasks over
multiple passages. Y-27632-pretreated H9 cells cultured on
CELLstart were dissociated to single cells and seeded
at 2.5×105cells/ml into a 125-ml spinner flask containing
60 ml of StemPro hESC SFM with 40 ng/ml bFGF and
Y-27632. Half of the medium was replaced every day without
further addition of Y-27632. After 3 to 4 days the suspension
cultures were passaged by dissociating the aggregates to sin-
gle cells using Accutase. This passaging process was repeated
every 3 or 4 days to maintain the H9 suspension culture for
a period of 64 days with a total of 21 passages. The cell num-
ber and viability from these suspension cultures were moni-
tored on the day of passaging. The results indicate the
cells in these cultures were able to maintain high and consis-
tent viability with an average viability of 92.2±3.0%
(Figure 4A). In addition, the expansion rate was consistent
throughout the 21 passages with an average expansion rate
of 4.3±0.4 per passage (Figure 4B). Based on this expansion
rate, the culture achieved an overall calculated expansion of
1.5×1013 fold by the end of passage 21 (Figure 4C). We also
tracked the undifferentiated state of the long-term suspen-
sion cultures during serial passaging by flow cytometric
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Figure 3 Determination of cell seeding density and cell split interval. H9 hESCs at density 1.5×105 and 2.5×105cells/ml were seed-
ed in 125 ml spinner flasks containing StemPro with 40 ng/ml bFGF with agitation rate 70 rpm. Cell aggregates were harvested from
days 1 to 6. (A) Morphology of cell aggregates from days 2 to 5. (B) Expression of pluripotency markers, Tra-1-60, Tra-1-80, and Oct-4,
from days 2 to 6 of cell aggregates were analyzed by flow cytometry. (C) Cell viability and (D) vital cell numbers were compared from
days 1 to 6.
393Scalable GMP compliant suspension culture system for human ES cellsanalysis. Cells collected from the initial CELLstart-adapted
adherent culture and the suspension cultures at passages 1,
5, 11, 16, and 21 showed that over 90% cell populations
expressed the pluripotency markers, Tra-1-60, Tra-1-81,
SSEA-4, and OCT-4 (Figure 4D), indicating the cells in the
suspension culture system retained appropriate expression
patterns. Cytogenetic analysis of the end culture revealed
that the cells maintained a normal karyotype (Figure 4E).
To assess if other hESC lines can be stably maintained in sus-
pension culture with spinner flasks, HES-2 and H1 lines wereFigure 2 Comparison of medium conditions for suspension cultures
were compared for growing hESCs in suspension cultures in the pres
6-well plates containing mTeSR1 (n=3), StemPro (n=3), and StemPro
of cell aggregates formed at days 1, 3, and 6. (B) Flow cytometry
(C) cell viability and (D) cell numbers were compared at days 3 and 6.propagated under the conditions described above for 9 pas-
sages. A repeat of H9 suspension culture was also included
in this set of experiment to test reproducibility of this cul-
ture system. The results from this experiment showed that
all 3 hESC lines can be stably maintained in suspension cul-
ture with an average expansion rate of 3.2±0.6, 3.8±0.6,
and 4.1±0.5 fold per passage for HES-2, H1, and H9, respec-
tively (Figure 4F and G). High viability was consistently ob-
served in these cultures with 89.8±2.0%, 90.7±1.6%, and
91.8±3.5% for HES-2, H1, and H9, respectively (Figure 4H).. Serum-free and defined media, mTeSR1 and StemPro hESC SFM,
ence of Y-27632. Single cell-dissociated H9 cells were seeded in
with 40 ng/ml bFGF (n=3) with orbital shaking. (A) Morphology
analysis of pluripotent markers, Tra-1-60, Tra-1-81, and Oct-4,
Error bars represent mean±SD.
394 V.C. Chen et al.After 9 passages in suspension culture, over 90% of the cell
populations were positive for Tra-1-60, Tra-1-81, SSEA-4,
and OCT-4 staining and less than 7% were positive for differ-
entiated marker SSEA-1 as analyzed by flow cytometry
(Figure 4I). Cytogenetic analysis showed the 3 cell lines
all maintained normal karyotypes (data not shown). Todemonstrate the utility of the suspension culture, we ex-
panded the HES-2, H1, and H9 lines in these suspension cul-
tures to generate 3 large-scale cell banks under cGLP or
cGMP conditions. The suspension cultures were initially ex-
panded in 125 ml spinner flasks and then were scaled up to
4 or 5×500 ml spinner flasks. After 3 to 4 passages in
395Scalable GMP compliant suspension culture system for human ES cellssuspension cultures, cells expanded in 500 ml spinner
flasks were used to generate 200 to 400 vial cell banks,
with 4×106 cells per vial. These results demonstrate that
all hESC lines tested can be serially passaged and expanded
in suspension culture with spinner flasks and can be practi-
cally scaled up to generate cell banks under cGMP and
cGLP conditions.Expansion rate and population doubling time of hES
in suspension and adherent cultures
The expansion rates of hESC lines, H9, H1 and HES-2, grown
in suspension were compared with adherent cultures on MEF
and CELLstart. In this study, suspension cultures were rou-
tinely passaged every 3 or 4 days as described in the previous
sections. Cells cultured on MEF were passaged every 5 or
6 days after reaching about 70% confluence, and cells on
CELLstart were passaged every 3 or 4 days after reaching
about 80–90% confluence. Cell lines maintained in both ad-
herent conditions were passaged at a ratio of 1:4. Cell cul-
tures were carried for a period of 22–28 days and viable
cell counts were determined every passage to determine
the expansion rate. The accumulative fold of expansion
was plotted against the passage number for all three lines
used in this study (Figure 5A–C). The results indicated that
the expansion rate of suspension culture was higher than
for cells cultured on MEF (Figure 5A and C) and was similar
to cells cultured on CELLstart (Figure 5A–C). Generally, sus-
pension cultures and adherent cultures on CELLstart dis-
played better cell viability at passaging. The viability of
HES-2, H1, and H9 in suspension cultures was 89.3±1.7%,
90.7±1.6%, and 91.8±3.5%, respectively and on CELLstart
adherent cultures was 93.6±2.0%, 90.6±8.0%, and 93.9±
2.5%, respectively.
In contrast, viability of HES-2 and H9 on MEF adherent
cultures was 81.5±9.5% and 85.5±5.0%, respectively. The
population doubling time was also assessed for H9 and
HES-2 lines that were cultured in both suspension and adher-
ent cultures. To determine the doubling time, the viable cell
number was determined each day for 6 days starting from
the day after the cells were seeded. The cell number was
then plotted against the days of culture and the doubling
time was calculated using the exponential regression meth-
od. The calculated population doubling time for HES-2 in sus-
pension and on MEF was 30.9 and 29.4 h, respectively; and
for H9 in suspension, on MEF, and CELLstart was 29.3, 26.1,
and 27.2 h, respectively. The similar doubling times ofFigure 4 Serial passaging and expansion of suspension cultures.
125 ml spinner flasks with 70 rpm agitation. Cells were passaged ev
over 90% in average and (B) consistent fold increase, approximately
calculated by fold increase of cell number at every passage. The a
reached over 1×1013 folds over 21 passages. (D) At passages 1, 5, 11
cultures were analyzed by flow cytometry for pluripotency marker
stability of the end culture was shown normal as analyzed by G-ban
and a repeat of H9 were cultured in suspension with 125 or 500 ml
rates reached over 50,000 folds for HES-2 and over 100,000 for H1 a
from 2 to 4.8 folds. (H) Cell viability was approximately 90% at pass
were analyzed by flow cytometry of pluripotent markers, Tra-1-6
SSEA-1 staining.suspension and adherent cultures indicate that cells in sus-
pension retain normal population doubling time. Taken to-
gether, these results demonstrate that the hESC suspension
culture displays comparable growth characteristics with ad-
herent cultures.
Characterization of pluripotency and differentiation
of hESCs cultured in suspension
The pluripotency of hESCs derived from suspension culture
was examined by assessing embryoid body (EB) and teratoma
formation. For EB formation assessment, H9 cell aggregates
were directly differentiated in EB formulation medium.
At day 6, EBs in suspension started to show complicated
and heterogeneous structures, indicative of differentiation
(Figure 6A). Gene expression analysis of EBs plated from ad-
herent cultures revealed that expression of Pou5f1 (OCT-4)
and Nanog decreased to undetectable levels within 6 days.
Expression of T (brachyury), Sox17, Sox1, and Tubb3
(beta-Tubulin III), representing genes of three germ layers,
were detected at different stages of EB differentiation
(Figure 6B). For teratoma formation, 2.5 million hESCs of
each H1, H9, and HES-2 derived from suspension cultures
were injected into immunocompromised mice and were able
to generate teratomas containing cell lineages of 3 germ
layers, including neuroepithelium, muscular cells and glandu-
lar epithelium (Figure 6C). These results demonstrated that
hESCs cultured in suspension maintain pluripotency.
Directed cardiomyocyte differentiation from cell
aggregates
We next tested if hESC aggregates derived from the suspen-
sion culture can be applied to directed differentiation. H9
cell aggregates from day 3 or 4 suspension culture were di-
rectly induced to cardiomyocyte differentiation in a spinner
flask using a serum-free and stage specific induction method
(Yang et al., 2008). At day 9 post-induction, contracting EBs
were observed. At day 19, flow cytometric analysis of differ-
entiated EBs showed that approximately 27% of the cell popu-
lation was positive for the cardiac-specific marker, Troponin T
(Figure 6D). By immunohistostaining EB sections, positive
staining for sarcomeric myosin heavy chain (sMHC) and βmyo-
sin heavy chain (βMHC) were observed (Figure 6E). Gene
expression analysis of the induced cells showed the expression
of a broad spectrum of cardiac-specific genes, Isl-1,
Nkx2.5, MYH6, Tnnt2, Myl2, and Myl7 (Figure 6F). TheseH9 hESCs at seeding density 2.5×105cells/ml were cultured in
ery 3–4 days for 21 passages. (A) Cells retained high viability,
4 folds in average at very passage. (C) The expansion rate was
ccumulated fold increase of the cell suspension culture stably
, 16, and 21, the undifferentiation rates of cells from suspension
s, Tra-1-60, Tra-1-81, SSEA-4, and Oct-4. (E) The chromosomal
ding karyotyping. With the same culture conditions, HES-2, H1,
spinner flasks for 9 passages. (F) The calculated cell expansion
nd H9. (G) Fold increase of cell number at every passage ranged
aging. (I) The undifferentiation rates of the suspension cultures
0, Tra-1-81, SSEA-4, and Oct-4, and a differentiated marker
Figure 5 Comparison of expansion rates of hESC cultured on feeder layer, CELLstart and in suspension. The expansion rates and cell
viability of HES-2, H1 and H9 cells cultured on MEF, CELLstart and in suspension were compared for 22–28 days of time periods.
The accumulative fold of expansion and cell viability was plotted against the days of cultures for all three lines used in this
study: (A–C) calculated fold increase of HES-2 (A), H1 (B), and H9 (C) cells grown on MEF, CELLstart, or in suspension culture
at every passage; (D–F) cell viability of HES-2 (D), H1 (E), and H9 (F) cells grown on MEF, CELLstart, or in suspension culture
at passaging.
396 V.C. Chen et al.results demonstrated that hESC aggregates generated from
these suspension cultures can be potentially used for
directed differentiation.Cryopreservation of hESC suspension culture
An objective of our hESC production system is to use serum-
free and defined conditions through all phases of adherent cul-
ture, suspension culture and cryopreservation. It has been
reported that inclusion of Y-27632 in cryopreservation medi-
um enhances survival rate and plating efficiency of hESCs atthaw (Li et al., 2009; 2008; Martin-Ibanez et al., 2008; Molla-
mohammadi et al., 2009). We therefore added Y-27632 into
StemPro hESC SFM containing 10% DMSO as cryopreservation
medium. Human ES cell aggregates from suspension culture
were single cell dissociated and cryopreserved in the freezing
medium. Upon thaw, HES-2, H1, and H9 cells showed a viabil-
ity of 86.0±3.0%, 92.1±2.0%, and 88.7±3.8%, respectively.
The thawed cells were plated at 1.5×106cells/well of 6-well
plates (approximately 1.56×105cell/cm2) on MEF and CELL-
start, and at 2.5×105cells/ml in spinner flasks for suspen-
sion culture. Cells thawed on MEF and CELLstart culture
reached 70–90% confluence in 4–7 days (Figure 7A and B),
397Scalable GMP compliant suspension culture system for human ES cellsand cells thawed into suspension were also able to form
and grow in cell aggregates (Figure 7C). Cells thawed
and seeded back into adherent and suspension cultures
were passaged and over 80 or 90% (82–99%) of the cell
population expressed pluripotency markers after 3 pas-
sages (Figure 7D). Cryopreserved cells thawed directly
into suspension culture expanded 1.7 fold at the first
passage followed by 2.6 to 4.5 fold increase at passages
2 to 5 (Figure 7E). These cultures also retained high per-
centages of cells expressing pluripotency markers as ana-
lyzed by flow cytometry (Figure 7D). These results
demonstrate that hESCs maintained in suspension cul-
tures can be cryopreserved in serum-free conditions in
the presence of Y-27632, and can be thawed back into ei-
ther adherent or suspension cultures for serial passaging
and expansion.Discussion
As pluripotent stem cells have moved forward to pre-
clinical and clinical studies, a robust scalable system for
hESC production under GMP or GLP conditions to provide
sufficient quality cells is essential. In the current study,
we have established a serum-free, feeder-free, and de-
fined system for the expansion of hESCs in suspension cul-
ture by optimizing media conditions, cell seeding density,
and cell passage interval. These hESCs can be cryopre-
served in a serum-free defined medium and can be success-
fully thawed into either adherent or suspension culture. We
demonstrate for the first time the feasibility of long-term
serial passaging of hESC suspension culture in spinner flasks
(over 20 passages) and practically use this culture system to
scale up the production of hESCs under cGMP or cGLP condi-
tions. Our study not only provides a scalable suspension cul-
ture method but also provides a strategy to optimize hESC
suspension culture.
Conventionally, expansion of hESC adherent culture re-
quires passaging the cells in small cell clumps, as cells
which have been dissociated to single cells show poor viabil-
ity and seeding efficiency (Amit et al., 2000; Reubinoff et
al., 2000; Thomson et al., 1998). Recently, several reports
have demonstrated that single cell-dissociated hESCs can
survive in suspension by forming cell aggregates. (Amit et
al., 2010; Krawetz et al., 2010; Olmer et al., 2010; Singh
et al., 2010; Steiner et al., 2010). Unlike mES cells, which
can form cell aggregates from single cells in suspension
(Cormier et al., 2006; Kehoe et al., 2008; zur Nieden et
al., 2007), hESCs require a ROCK inhibitor, Y-27632, to
form cell aggregates and propagate. Formation of cell aggre-
gates appears to be a critical step for hESCs to survive and
expand in suspension and the ROCK inhibitor is a key factor
for this step.
We have found that when hESC aggregates are main-
tained in suspension culture, it is critical to control the
size of the aggregates to ensure efficient expansion and
quality of hESCs. It is a reasonable speculation that nutrients
and cytokines will be difficult to penetrate into cell aggre-
gates to maintain hESC growth as cell aggregates gain in
size. We selected culture conditions which can generate a
great number of cell aggregates in small sizes at the initial
stage to achieve a better expandability. We found passagingcells every 3–4 days provided the optimal expansion rate. In
addition we found that cultures in StemPro media formed
small and homogeneous aggregates and resulted in a better
expansion rate than cultures in mTeSR media. At lower cell
seeding density, 1.5×105cells/ml, initial sizes of cell aggre-
gates appeared slightly smaller than those of seeding at
2.5×105cells/ml but we also noticed that aggregates
appeared less at lower seeding density, resulting in a lower
cell yield. Previous studies have shown great expansion
rates of their hESC suspension cultures using much lower
seeding density, while the cell yields were not comparable
with adherent cell cultures (Krawetz et al., 2010; Olmer
et al., 2010). In contrast, a higher seeding cell density re-
sults in higher cell yield but lower expansion rate (Singh
et al., 2010). Therefore, it is crucial to optimize cell seed-
ing density to ensure proper expansion rates and cell yields
of hESC suspension culture. As the growth characteristics of
hESC lines are varied, the passaging interval and cell seed-
ing density may also need to be optimized for different
lines.
For large-scale manufacture of hESCs, it is crucial to val-
idate a culture system by demonstrating a long-term culture
which can be stably passaged and expanded to the level suf-
ficient for making master cell bank to working cell bank, de-
velopment cell bank, and differentiation. As shown by the
work of Singh et al., the growth characteristics of hESCs in
suspension cultures using static low-attachment plates, stir-
red Petri dishes, and spinner flask are varied, indicating that
suspension cultures with different types of vessels need to
be optimized individually. Though the long-term passaging
of suspension cultures in small-scale vessels have been dem-
onstrated, these culture conditions may not be suitable for
long-term cultures with large-scale vessels. While two stud-
ies have shown serial passaging of suspension culture using
spinner flasks with small volume for 3 to 5 passages, the sus-
pension culture system we established is able to consistently
expand hESCs for over 20 passages and scale up to 500 ml
spinner flasks, demonstrating the feasibility of large-scale
cell banking using the suspension culture system.
Maintenance of hESCs in suspension culture not only avoids
MEF or matrix contamination but it also provides a system
more amenable to scalable and controllable automation. It is
interesting to note that the cell density achieved in the
current suspension culture is approximately 1×106cells/ml,
similar to the cell density seen in the adherent culture. How-
ever, it is well accepted that suspension culture offers many
advantages over the adherent culture, with the scalability
being the most important factor. Since the spinner flask sys-
tem used in this study is themost primitive form of bioreactor,
it is reasonable to assume that themaximal cell density can be
significantly increased when a more sophisticated bioreactor
is used to provide better control of all process parameters, in-
cluding the O2 tension that has been reported to affect the
growth of the hESCs. In addition, the cell density may also be
increased using well established cell culture strategies, such
as the fed-batch and perfusion systems that have been
reported to increase cell density by 5 to 10 folds for numerous
mammalian cell lines (Huang et al., 2010; Tao et al., 2011).
Expanding hESCs in suspension culture using bioreactors also
reduces the number of culture vessels for banking and signifi-
cantly reduces labor for cell harvesting, dissociation, and pas-
saging. We believe that the suspension culture system
398 V.C. Chen et al.presented here could be the foundation for the development
of large-scale hESC culture system to address the demand of
large-scale production of the hESCs for clinical applications,
as the suspension culture can readily be scaled up 1000 to
10,000 folds in a single commercial size bioreactor.
The EB formation method has been broadly used to direct
ES cell differentiation to tissue-specific cell lineages. Unlike
mES cells, hESCs usually form EBs very inefficiently. Addi-
tionally, sizes and morphology of the formed EBs are highly
heterogeneous. An efficient cell specific-differentiation pro-
tocol using EB method requires the initial EBs to be homoge-
neous to generate more controllable, predictable, andconsistent results. The hESC suspension culture system we
developed may provide a promising way to conquer the chal-
lenging step of EB formation. As we showed previously, hESC
aggregates generated from our suspension culture system
were homogeneous in size and shape. These undifferen-
tiated cell aggregates can serve as starting material for EB
formation. In this study, we demonstrated that these cell ag-
gregates could be directly differentiated to cardiomyocytes
in a spinner flask containing appropriate induction media.
Therefore, our suspension culture system not only over-
comes the difficulty of initial EB formation but also provides
a promising scalable system for hESC differentiation.
Figure 7 Cryopreservation of hESC suspension culture. (A–C) hESCs harvested from suspension culture were cryopreserved in single
cells with StemPro containing 10% DMSO and Y-27632. HES-2 cells were thawed on MEF (A), CELLstart (B) or in suspension (C) and were
passaged for 3 times. H9 cells thawed directly into suspension culture were passaged and expanded for 5 times. (D) Flow cytometry
analysis of pluripotency markers, Tra-1-60, Tra-1-81, SSEA-4, and Oct-4, for HES-2 cultures 3 passages post-thawed on MEF, CELLstart
and in suspension, and for H9 cultures 5 passages post-thawed in suspension were shown in the tables. (E) Fold increase of H9 at every
passage after thawed in suspension was shown in the chart.
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We have developed procedures from cell adherent cultures,
suspension cultures to cryopreservation under feeder-free,
serum-free, and defined culture conditions. More important-
ly, hESCs can be maintained and consistently expanded in
our suspension culture system for long-term culture while
retaining normal karyotype, appropriate marker expression,
and pluripotency. Additionally, the cryopreserved hESCs can
be directly thawed and expanded in this suspension culture
system. With these advantages, the suspension culture can
serve as an alternative system for routine maintenance of
hESCs. Furthermore, we have used the suspension culture
system to produce 3 hESC banks under cGMP and cGLPFigure 6 Pluripotency of hESCs expanded in suspension. At the end
vivo differentiation analysis. Day 3 cell aggregates from the suspen
medium in a spinner flask for EB formation assay. (A) At day 6, cell
(B) Alternatively, day 1 EBs from suspension culture were plated on M
differentiation. Cells differentiated in adherent cultures were harve
tative RT-PCR for the expression of pluripotency genes, Oct-4 and N
and SOX17. (C) For teratoma assay, 2.5 million hESCs of each H1, H
immuno-deficient mice. Teratoma cell mass was observed 8 weeks
and 13 weeks after injection. H1 ectoderm: red arrow indicates gan
derm: arrow indicates smooth muscle cells; endoderm: arrow indica
gangalio-neuronal tissue; mesoderm: arrow indicates smooth muscle
HES-2 ectoderm: arrow indicates neuroblastic rosettes; mesoderm: a
intestinal-like glandular cells. Sections stained with hematoxylin and
ed cardiomyocyte differentiation in suspension in a spinner flask u
dissociated for flow cytometry analysis of cardiac Troponin T positiv
histochemistry was carried out with staining of sMHC and βMHC. Gree
staining for nuclei. (F) Expression of cardiac-specific genes, ISL-1, Nx
quantitative RT-PCR.conditions. Our cGMP scalable technology of hES suspension
culture will provide an efficient and facile manufacturing
system to generate sufficient clinical grade of hESCs with
consistent and predictable characteristics for research and
clinical applications.Materials and methods
Human ES cell adherent cultures
MEF culture
hESC lines were cultured on mytomycin C-inactivated
MEFs (Millipore) with DMEM supplemented with 20% knockoutof suspension culture, H9 cells were subjected to in vitro and in
sion culture were directly differentiated with serum-containing
aggregates differentiated into EBs with complexed structures.
atrigel-coated dishes with serum-containing medium for further
sted at days 2, 4, 6, 9, 12, and 16 and were analyzed by quanti-
anog, and genes of 3 germ layers, SOX 1, TUBB3, T (Brachyury),
9, and HES-2 from the suspension cultures were injected into
post cell injection. The tissue mass was dissected between 9
glion cells, blue arrow indicates ganglio-neuronal tissue; meso-
tes intestinal-like glandular cells. H9 ectoderm: arrow indicates
cells; endoderm: arrow indicates intestinal-like glandular cells.
rrow indicates smooth muscle cells; endoderm: arrow indicates
eosin. (D) The H9 cell aggregates were also subjected to direct-
nder serum-free conditions. EBs at day 19 were harvested and
e cell population. (E) The EBs were also sectioned and immuno-
n fluorescence indicated positive cells. Blue fluorescence is DAPI
k2.5, MYH6, TNN-2, MYL2, and MYL7 of the EBs were analyzed by
400 V.C. Chen et al.serum replacement, 1 mM L-glutamine, non-essential amino
acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), and
4 ng/ml human recombinant basic fibroblast growth factor
(bFGF; Invitrogen). Media were change every day. Cell cul-
tures were passaged every 5–6 days. At passaging, cells were
treated with 200 u/ml collagenase (Invitrogen) for 5–10 min
at 37 °C, and then gently pipetted to break the big clumps
into even sizes. Cells were passaged at a split ratio of 1:3 or
1:4.CELLstart culture
Manufacture's culture conditions were followed for CELL-
start (Invitrogen). Briefly, the CELLstart matrix was diluted
in PBS containing Ca2+ and Mg2+ at 1:50 dilution. Tissue cul-
ture vessels were coated for 2 h at 37 °C before use. Cell cul-
tures were treated with Accutase (Millipore) for 1–2 min at
37 °C. Accutase was removed and replaced with fresh Stem-
Pro medium (Invitrogen) supplemented with 0.1 mM β-
mercaptoethanol and 8 ng/ml human recombinant bFGF,
and then the big clumps were gently pipetted to break into
even sizes. Cells were seeded at ratio of 1:3 or 1:4 into CELL-
start-coated vessels.Human ES cell suspension culture
Prior to suspension adaptation, hESCs were maintained in
CELLstart-coated plates with StemPro hESC SFM supplemen-
ted with 8 ng/ml bFGF and 0.1 mM β-mercaptoethanol. For
the initial suspension adaptation, hESCs are first dissociated
into single cells using Accutase for 3–5 min after 1 h of 10 μM
Y-27632 (EMD Chemicals) treatment. After wash the single
cells were seeded in even suspension at a density of 1.5 to
2.5×105cells/ml in mTeSR, or StemPro supplemented with
8 or 40 ng/ml bFGF and 0.1 mM β-mercaptoethanol. To en-
hance formation of cell aggregate, 10 μM Y-27632 were
added into the media. Single cell suspension was seeded in
6-well plates with orbital shaking at 80 rpm or spinner flasks
with magnetic stirrers (Thermo Scientific 50119114) set at
70 RPM. Subsequent medium changes were performed daily
via demi-depletion using the same medium without Y-
27632. Cells are passaged every 3–4 days post-seeding via
dissociation into single cells with Accutase and seeded at
1.5 to 2.5×105cells/ml in the same medium. Cultures were
maintained in a 5% CO2 air environment with 95% relative hu-
midity at 37 °C.Flow cytometry
Cell surface markers
Dissociated single cells were washed in PBS, resuspended
in FACS buffer (0.5% BSA in PBS) and incubated with primary
antibodies on ice for 30 min. After incubation, cells were
washed in FACS buffer and incubated with secondary anti-
body for 30 min on ice. Cells were washed, resuspended
with FACS buffer and analyzed by Accuri C6 flow cytometry
(Accuri). Primary antibodies were mouse IgM anti-Tra-1-60,
mouse IgM anti-Tra-1-81, mouse IgM anti-SSEA-1 (Millipore),
and mouse IgG3 anti-SSEA-4 (R&D systems). Secondary anti-
body was R-PE goat anti-mouse IgM (Southern Biotech).Intracellular markers
Cells were fixed in 4% paraformaldehyde solution (USB) in
PBS for 5 min at room temperature. Subsequently, cells
were washed in PBS and permeabilized with buffer contain-
ing PBS, 0.1% soponin and 0.1% BSA, for 10 min at room tem-
perature. Cells were resuspended in permeabilization buffer
and stained with antibodies as procedures mentioned above
using permeabilization buffer. Primary antibodies were
mouse IgG2b anti-Oct-4 (Santa Cruz) and mouse IgG1 anti-
Troponin-T (Neomarkers). Secondary antibody was R-PE
goat anti-mouse IgG (Southern Biotech).
Alkaline phosphatase (AP) staining
A Millipore's AP detection kit was used to characterize ES
cells for AP activity. The staining was performed following
the procedure described in the kit.
Quantitative RT-PCR
Total RNA from cells was extracted using RNeasy kit
(Qiagen). Complementary DNA was synthesized from 2 μg
of RNA per sample using iScript cDNA Synthesis Kit (BioRad).
Real time PCR was performed to determine expression level
of each gene. cDNA corresponding to 0.1 μg of total RNA was
used as a template in the PCR consisting of MasterMix and
TaqMan gene expression system (Applied Biosystems),
according to the manufacturer's instructions. Quantitative
PCR was performed with an Stratagene MX3000P System
using the default thermal cycling conditions (Initiate at
50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles at
95 °C for 15 s and 60 °C for 60 s). Relative quantification
was performed using the comparative cycle threshold meth-
od (2−ΔΔCT). Primer sets were purchased from Applied Bio-
systems (Supplemental Table 1).
Immunohistochemistry
Whole mounted staining
Staining-Human ES cell aggregates from suspension of
days 2 or 3 were harvested. After washed in PBS, the cells
were fixed with 4% PFA for overnight, then permeabilized
and blocked with buffer containing 0.3% BM blocking powder
(Roche), 5% normal serum, 5% FBS, and 0.1% Triton, for
1 days at 4 °C with gently rocking. Primary antibodies were
added at 10 μg/ml for overnight at 4 °C with gently rocking.
Primary antibodies used were anti-Oct4, anti-Tra-1-60 (Milli-
pore), anti-CD324 (eBioscience), and Nanog (H-155, Santa
Cruz). After wash with PBS containing 0.1% Tween-20 and
0.5% BSA, secondary antibodies (FITC-conjugated IgG and
Rhodamine-conjugated IgG) or Streptavidin Cy5 were added
at 1:400 dilution for overnight. After additional wash, the ag-
gregates were mounted using Prolong Gold anti-fade reagent
with DAPI (Invitrogen).
Cross-sectional staining
Samples were processed by Pathology Core Facility at
City of Hope. The slides were blocked in 10% normal serum
with 1% BSA in TBS for 2 hours at room temperature. Primary
antibodies, anti-sMHC (MF20, Developmental Studies Hybrid-
oma Bank) and anti-βMHC (Millipore), were added at 1:100
401Scalable GMP compliant suspension culture system for human ES cellsdilution for overnight at 4 °C. The slides were then washed
and FITC-conjugated IgG antibody were added at 1:400 dilu-
tion for 1 h at room temperature and mounted. The whole-
mounted and cross-sectional stainings were observed under
a LSM 510 Meta Inverted 2 Photon confocal laser scanning
microscope.Cell population doubling time
Cells maintained on MEF or CELLstart adherent or in suspen-
sion culture were passaged as mentioned previously. For ad-
herent cultures, cells were seeded in 6-well plates, 3 wells
for each time point. For suspension cultures, cells were
seeded at 2.5×106cells/ml in 125-ml spinner flasks. After
seeding, cells were harvested from wells or aliquoted from
spinner flasks everyday from days 1 to 6. Cells were dissoci-
ated to single cells with Accutase, and the number of live
cells was determined by trypan blue exclusion. Growth
curves were generated from these data, and the approxi-
mate doubling time was calculated using linear regression.
Data points in the linear phase were input into the program,
Doubling Time Software v1.0.10 (http://www.doubling-
time.com) (Roth, V. 2006), to calculate population doubling
time.Karyotype analysis
Karyotypes of hESCs were analyzed by Cytogenetics Core Fa-
cility at City of Hope. Briefly, cells were harvested according
to standard methods and fixed in 3:1 methanol:acetic acid.
Slides were GTG banded. Twenty mitotic cells were digitized
and karyotyped. Karyograms were reviewed and aberrations
were described according to ISCN (2009).Teratoma assay
hESCs at 2.5×106 cells in 0.1 ml serum-free medium were
subcutaneously injected into dorsal area of NOD/SCID/IL2R
gamma null mice (NSG mice, male, 8–10 weeks old, from
Jackson Laboratory, Bar Harbor, Maine) with 23G needle.
After the teratoma grew to size about 10 mm in diameter,
the mice were euthanized and the teratoma were excised,
fixed with 10% formalin, and sent to pathological core lab
for paraffin sectioning and H&E staining. The animal proce-
dures were approved by IACUC of Beckman Research Insti-
tute of the City of Hope.EB formation assay
Cell aggregates were harvested, washed with PBS, and resus-
pended in embryoid body (EB) formation medium (Millipore)
supplemented and cultured in suspension. Medium was chan-
ged every other day via demi-depletion with EB formation
medium for the remainder of the experiment. Alternatively,
the EBs can be further differentiated on adherent surface by
plating day 1 EBs onto glass-bottom culture dishes (MatTek)
coated with Matrigel (BD). Subsequent medium changes
were performed every other day with the same EB differen-
tiation medium. Differentiated cell cultures were collectedat days 2, 4, 6, 9, 12, and 16 for detection of markers for
cell lineages of 3 germ layers.Cardiomyocyte differentiation
Prior to differentiation in suspension, hESCs were maintained
in the suspension culture system as described. For cardiac dif-
ferentiation, procedures described in previous report (Yang et
al., 2008) were used with minor modifications. Briefly, hESC
aggregates derived from suspension cultures were directly dif-
ferentiated in basal medium containing 0.5 ng/ml of BMP-4
(R&D systems) for 1 day. On induction days 1–4, 10 ng/ml
BMP-4, 5 ng/ml human bFGF, and 6 ng/ml Activin A (R&D sys-
tems) were added. For induction days 4–8 basal medium con-
taining 10 ng/ml VEGF (R&D Systems) and 150 ng/ml Dkk-1
(R&D Systems) was used. From induction day 8 until the end
of the experiment, basal medium with 10 ng/ml VEGF and
10 ng/ml human bFGF was used. Cultures were maintained in
a spinner flask with stirring rate at 50 rpm.Cryopreservation
ES cell aggregates from suspension cultures were dissociated
to single cells by Accutase and washed as mentioned previ-
ously. A freeze medium containing 90% StemPro hESC SFM,
10% DMSO, and 10 μM Y-27632, was compounded to cryopre-
serve hESCs. Cells were aliquoted into cryovials (Corning)
with 4×106 cells in 1 ml per vial. The cryovials containing
hESCs were placed in Mr Frosty and stored at −80 °C. After
24 h, the cryovials were transferred to liquid nitrogen for
long-term storage.
Supplementary data to this article can be found online at
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